FindTrial
Sign In

Efficacy and safety analysis of monthly minodronic acid in Japanese osteoporotic patients switched from traditional bisphosphonates

Efficacy and safety analysis of monthly minodronic acid in Japanese osteoporotic patients switched from traditional bisphosphonates - Usefulness of switching to monthly minodronic acid in Japanese osteoporotic patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000009575
Enrollment
600
Registered
2012-12-18
Start date
2011-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Minodronic acid (50mg/month) Another BPs

Sponsors

Ken-Ai Memorial Hospital
Lead Sponsor
Sanzai Hospital Tsurukami Orthopaedic and Rheumatoid Clinic Kitakyushu General Hospital Makiyama Chuou Hospital Obase Hospital Katsuki Neurosurgery and Orthopaedic Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with osteoporosis 2. Patients who were taking traditional BPs 3. Patients giving informed consent

Exclusion criteria

Exclusion criteria: Patients with 1. Esophageal stricture or achalasia 2. Incapability in remaining upright for 30 min 3.Hypersensitivity to minodronic acid and other bisphosphonates 4. Hypocalcemia 5. Pregnancy 6. Aphagia, Esophagitis, Gastritis, Duodenitis or Ulcers 7. Severe renal dysfunction

Design outcomes

Primary

MeasureTime frame
Bone mineral density Bone turnover marker—

Secondary

MeasureTime frame
Low back pain Abdominal symptoms Preference and adherence for BPs Osteoporotic fracture—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026